Financials Acelyrin, Inc.

Equities

SLRN

US00445A1007

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
4.13 USD -2.13% Intraday chart for Acelyrin, Inc. -5.92% -44.64%

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 726.2 409 - -
Enterprise Value (EV) 1 726.2 533.1 338.2 409
P/E ratio -1.37 x -1.35 x -1.02 x -1.29 x
Yield - - - -
Capitalization / Revenue - - - 9.77 x
EV / Revenue - - - 9.77 x
EV / EBITDA - -1.28 x -0.77 x -
EV / FCF - -1.73 x -0.84 x -0.87 x
FCF Yield - -57.9% -119% -115%
Price to Book - -1.74 x -14.2 x -
Nbr of stocks (in thousands) 97,339 99,027 - -
Reference price 2 7.460 4.130 4.130 4.130
Announcement Date 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - - - - 41.86
EBITDA 1 - - -416.4 -437.4 -
EBIT 1 - -422.1 -368.4 -441.8 -506.9
Operating Margin - - - - -1,210.93%
Earnings before Tax (EBT) 1 - -381.6 -310.3 -413.1 -479.2
Net income 1 -64.77 -381.6 -310.3 -413.1 -479.2
Net margin - - - - -1,144.66%
EPS 2 -21.09 -5.430 -3.054 -4.048 -3.200
Free Cash Flow 1 - - -308.5 -401.5 -470
FCF margin - - - - -1,122.77%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 4/13/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - - - - -
EBITDA 1 - - - - -82.72 -102.9 -104.9 - - -
EBIT 1 - -42.7 -94.42 -105.1 -82.77 -84.63 -91.93 -101.4 -115.9 -117.5
Operating Margin - - - - - - - - - -
Earnings before Tax (EBT) 1 - -26.04 -83.94 -95.21 -34.97 -68.06 -79.22 -96.14 -115.9 -117.5
Net income 1 -176.4 -26.04 -83.94 -95.21 -34.97 -68.06 -79.22 -96.14 -115.9 -117.5
Net margin - - - - - - - - - -
EPS 2 -8.610 -0.4000 -0.8700 -0.7500 -0.3600 -0.6867 -0.7967 -0.9300 -1.160 -1.170
Dividend per Share - - - - - - - - - -
Announcement Date 6/15/23 8/14/23 11/7/23 3/28/24 5/14/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 - - 124 - -
Net Cash position 1 - - - 70.8 -
Leverage (Debt/EBITDA) - - -0.2982 x - -
Free Cash Flow 1 - - -309 -402 -470
ROE (net income / shareholders' equity) - - -80.9% -207% -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share 2 - - -2.370 -0.2900 -
Cash Flow per Share - - - - -
Capex 1 - - 2.5 2.33 3
Capex / Sales - - - - 7.17%
Announcement Date 4/13/23 3/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.13 USD
Average target price
22.17 USD
Spread / Average Target
+436.72%
Consensus
  1. Stock Market
  2. Equities
  3. SLRN Stock
  4. Financials Acelyrin, Inc.